Humana Inc. $HUM Position Reduced by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its position in Humana Inc. (NYSE:HUM) by 60.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,052 shares of the insurance provider’s stock after selling 14,000 shares during the period. Handelsbanken Fonder AB’s holdings in Humana were worth $2,355,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Elevation Point Wealth Partners LLC acquired a new position in Humana in the 2nd quarter worth approximately $32,000. Mather Group LLC. purchased a new stake in shares of Humana in the third quarter valued at $34,000. AlphaCore Capital LLC acquired a new stake in shares of Humana in the second quarter worth $39,000. Private Wealth Management Group LLC grew its holdings in shares of Humana by 47.5% during the third quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock valued at $39,000 after buying an additional 48 shares in the last quarter. Finally, SJS Investment Consulting Inc. raised its position in Humana by 19,300.0% during the third quarter. SJS Investment Consulting Inc. now owns 194 shares of the insurance provider’s stock valued at $50,000 after buying an additional 193 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Down 3.1%

Shares of HUM stock opened at $181.45 on Wednesday. Humana Inc. has a 12 month low of $169.61 and a 12 month high of $315.35. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 0.70. The firm has a market cap of $21.88 billion, a PE ratio of 18.48, a price-to-earnings-growth ratio of 2.02 and a beta of 0.44. The stock has a 50 day moving average of $226.42 and a 200-day moving average of $254.27.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. The business had revenue of $32.64 billion for the quarter, compared to analyst estimates of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. Humana’s revenue was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, equities analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Stockholders of record on Friday, March 27th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 2.0%. Humana’s dividend payout ratio is currently 36.05%.

Insider Buying and Selling at Humana

In other news, insider Sanjay K. Shetty bought 810 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were acquired at an average cost of $185.21 per share, with a total value of $150,020.10. Following the completion of the transaction, the insider directly owned 11,657 shares in the company, valued at $2,158,992.97. This represents a 7.47% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.37% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on HUM. Zacks Research lowered Humana from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 1st. Sanford C. Bernstein restated an “outperform” rating and set a $344.00 price target on shares of Humana in a report on Tuesday, January 6th. Morgan Stanley set a $146.00 price objective on shares of Humana in a research report on Thursday, February 12th. Wells Fargo & Company cut their target price on shares of Humana from $290.00 to $206.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 18th. Finally, TD Cowen decreased their target price on shares of Humana from $260.00 to $173.00 and set a “hold” rating for the company in a research note on Friday, February 13th. Seven equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and a consensus price target of $225.48.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.